Clinical trials
Advance Solid Tumors clinical trials
Below are recruiting advance solid tumors clinical trials, each written for real people, not researchers. We’re tracking 1,378 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04775485RecruitingPhase 2
Targeted medicine for children with certain brain or solid tumors
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
San Francisco, CaliforniaAges 6 months–25 years - NCT06258304RecruitingPhase 1
Testing a new immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug, GIGA-564, for people with advanced solid tumors that have not responded to or have returned after standard treatments. The goal is to see if the drug is safe and effective, and to find the best dose.
Bethesda, MarylandAges 18 years+ - NCT06431243RecruitingPhase 1/Phase 2
Purinostat Mesylate for advanced solid tumors
This trial tests a new drug called Purinostat Mesylate, either alone or combined with other drugs, in people with advanced solid tumors (including breast cancer) that have not responded to standard treatments. The goal is to see if the drug can help shrink tumors or slow their growth.
Guanzhou, GuangzhouAges 18–75 - NCT06094556RecruitingPhase 1
A study of SHR-1826 for advanced solid tumors
This trial tests a new drug called SHR-1826 for people with advanced solid tumors that have not responded to or are no longer helped by standard treatments. It is an early-phase study (Phase 1) to see if the drug is safe and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT07205718RecruitingPhase 1/Phase 2
Study of TAK-188 for advanced solid tumors
This trial tests a new medicine, TAK-188, for people with certain advanced cancers that have not responded to standard treatments. The goal is to see if it can help shrink or slow the growth of the cancer.
Santa Monica, CaliforniaAges 18 years+ - NCT07208773RecruitingPhase 1/Phase 2
Study of YL201 and Ivonescimab for advanced solid tumors
This trial tests a new drug combination (YL201 and Ivonescimab) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Guangzhou, GuangdongAges 18 years+ - NCT07204340RecruitingPhase 1
TLN-372 for advanced KRAS-mutant solid tumors
This trial tests a new drug called TLN-372 for people with advanced solid tumors that have a KRAS mutation. It aims to see if the drug is safe and effective for these cancers.
Birmingham, AlabamaAges 18 years+ - NCT07207707RecruitingPhase 1
KQB548 for advanced solid tumors with KRAS G12D mutation
This trial tests a new drug called KQB548 for people with certain advanced cancers (pancreatic, colorectal, or lung) that have a specific genetic change called KRAS G12D. It's for those whose cancer has continued to grow despite previous treatments.
La Jolla, CaliforniaAges 18 years+ - NCT07208136RecruitingPhase 1
A study of JMKX005425 for certain advanced solid tumors
This trial tests a new drug called JMKX005425 for people with advanced solid tumors that have a specific genetic feature called MSI-H or dMMR. If you have this feature and your cancer has not responded to other treatments, this study may offer a new option.
BeijingAges 18–80 - NCT05473624RecruitingPhase 1
Test drug HRS-1167 for advanced cancers that need new options
This early study (Phase 1) tests whether HRS-1167 can be given safely to people with advanced solid tumors. It also looks for early signs of activity, especially in cancers with HRR gene mutations (like ovarian, breast, pancreatic, and prostate cancers).
Beijing, Beijing MunicipalityAges 18 years+ - NCT05749432RecruitingPhase 1
Testing a new medicine for advanced solid tumors
This early-phase study (Phase 1) tests Hemay181, a new cancer medicine, in people with advanced solid tumors that have not been controlled by standard treatment. The goal is to see how the medicine works in the body and whether it can shrink or control tumors safely.
Beijing, Beijing MunicipalityAges 18–65 - NCT07195916RecruitingPhase 1
Testing a new drug for advanced solid tumors and blood cancers
This trial tests a new drug called INCA036873, which targets CD70 on cancer cells, for people with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The goal is to see if it is safe and effective against these tough-to-treat cancers.
Duarte, CaliforniaAges 18 years+ - NCT07193511RecruitingPhase 1/Phase 2
A new drug for advanced bladder and other solid tumors
This trial tests a new drug, AVZO-103, alone or with other treatments, for people with advanced bladder cancer or certain other solid tumors. It aims to find out if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT07202364RecruitingPhase 2
Study of YL202 for advanced solid tumors
This trial tests a new drug called YL202 for people with advanced solid tumors (like lung, colon, or cervical cancer) who have already tried 1-2 standard treatments. It aims to see if YL202 can shrink tumors or slow their growth.
Changsha, HunanAges 18 years+ - NCT07197554RecruitingPhase 1
A study of an experimental drug for advanced solid tumors
This trial tests a new drug, ST-01156, designed to attack cancer cells by breaking down a protein called RBM39. It may be an option for people with advanced solid tumors that have not responded to other treatments.
Duarte, CaliforniaAges 16 years+ - NCT07197827RecruitingPhase 1/Phase 2
YL242 for advanced solid tumors study
This trial tests a new drug called YL242 in people with advanced solid tumors that have not responded to prior treatment or have not been treated yet. It looks at safety, how well the drug works, and includes different groups based on cancer type and prior therapy.
New Haven, ConnecticutAges 18 years+ - NCT06895928RecruitingPhase 2
Testing SHR-A2102 for advanced solid tumors
This trial tests a new drug called SHR-A2102, alone or with other cancer treatments, for people with advanced solid tumors that haven't responded well to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
Taiyuan, ShanxiAges 18–70 - NCT06940349RecruitingPhase 1/Phase 2
Palbociclib and sunitinib for advanced solid tumors
This study tests a combination of two oral drugs—palbociclib and sunitinib—for people with advanced solid tumors that have not responded to other treatments. The goal is to see if these drugs together can help shrink or slow the growth of the cancer.
Petah TikvaAges 18 years+ - NCT05978492RecruitingPhase 1
Study of TXN10128 for advanced solid tumors
This trial is testing a new drug, TXN10128, for people with advanced solid tumors that have stopped responding to other treatments. It may be an option if standard treatments haven't worked or aren't suitable.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT06907628RecruitingPhase 1
Testing SHR-3792 for advanced solid tumors
This trial tests a new drug called SHR-3792 for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the drug is safe and how it affects the tumors.
Jinan, ShandongAges 18–75 - NCT07190469RecruitingPhase 1
PQ203 for advanced solid tumors like triple-negative breast cancer
This early-phase trial tests a new drug called PQ203 for people with advanced solid tumors, including triple-negative breast cancer, that have stopped responding to standard treatments. It helps doctors learn whether the drug is safe and how it affects tumors.
Houston, TexasAges 18 years+ - NCT07185243Recruiting
Study of virus injection plus immunotherapy for advanced solid tumors
This study tests a new combination treatment: a modified virus (hV01) injected directly into a tumor, plus a drug that helps your immune system attack cancer cells (PD-1 inhibitor). It is for people with advanced solid tumors that have not responded to standard therapies.
Xiamen, FujianAges 18–75 - NCT07189949RecruitingPhase 1
Study of HRS-2329 for advanced solid tumors with RAS changes
This trial tests a new drug, HRS-2329, for people with advanced solid tumors that have a RAS mutation or amplification and haven't responded to standard treatments. It aims to see if the drug can help shrink or control the tumors.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07192107RecruitingPhase 1/Phase 2
Study of MHB042C for advanced solid tumors
This trial tests a new drug called MHB042C for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective.
Guangzhou, GuangdongAges 18 years+
Hear when a new Advance Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advance solid tumors?
- Yes. Clin2 currently lists 1,378 recruiting advance solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advance solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advance solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.